This session will review current evidence based guidelines as well as the basis for guidelines pertaining to the treatment of esophageal and gastric cancer. Worldwide changes in epidemiology will be discussed. Current treatment strategies will be reviewed and compared.

IJROBP Journal SA-CME activity for April 1, 2018 (Volume 100, Issue 5) provides practitioners with the  knowledge to make competent recommendations when they meet patients with borderline resectable pancreatic cancer.

IJROBP Journal SA-CME activity for March 15, 2018 (Volume 100, Issue 4) reviews the data available for treating rectal cancer in elderly patients, their ability to tolerate treatment and available options for achieving the correct balance between therapeutic opportunity and therapeutic b

This activity on Gastrointestinal Cancer will provide a review of the most highly rated abstracts in the GI track from the ASTRO 2017 Annual Meeting. This activity will highlight results of technological advances and clinical research that will provide the attendees with knowledge to manage patie

IJROBP Journal SA-CME activity for February 1, 2018 (Volume 100, Issue 2) provides practitioners with the knowledge needed to discuss treatment effects on non tumor liver (“normal” liver) in patients treated for hepatocellular cancer.

The first session will provide a clinical update on the optimal management of upper GI malignancies including esophageal cancer, gastric cancer and pancreatic cancer.

Practical Radiation Oncology Journal SA-CME selection for March-April 2017 (Volume 7, Issue 2) explores the technology and technique of the Use of MRI in guiding target volume and normal structure definition in pancreas cancer to develop contouring guidelines. 

IJROBP Journal SA-CME activity from September 1, 2015 (Vol. 93, Iss. 1, pg. 16-25) examines quality of life after SBRT for liver cancer. This course is available from August 14, 2015, through 11:59 p.m. Eastern time on August 13, 2017.

Treatment of rectal cancer has improved greatly over recent decades.

This session will cover key concepts related to implementing intensity modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT) gastrointestinal (GI) cancers. Updates on clinical outcome data using IMRT and SBRT, including survival and toxicity, will be presented.